Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being ...

The trial examined the effect of Eli Lilly’s glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide, which is marketed as Mounjaro, on the clinical trajectory of patients with HFpEF and ...

In the phase 3 SURMOUNT-3 trial, tirzepatide (Mounjaro) demonstrated clinically meaningful added weight loss in adults with obesity without diabetes who already had at least 5% weight loss after a ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone ...

Tirzepatide was evaluated in 1,032 adults who had pre-diabetes at randomization and obesity or overweight for a treatment period of 176 weeks, followed by a 17-week off-treatment period (193 weeks ...

Tirzepatide improves kidney outcomes among patients with prediabetes, overweight or obesity, and preserved estimated glomerular filtration rate (eGFR), according to study results presented at the ...

By Hugo Francisco de Souza A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ...